Instrument Inactif

Communiqués Saniona AB Nasdaq Stockholm

Actions

SE0005794617

Recherche biotechnologique et médicale

Temps réel estimé Cboe Europe 17:25:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
11,94 ^SEK	-60,35%		-4,59%	-15,63%

10/08	La Bourse de Stockholm entame la semaine en repli, l'indice OMXS30 cède 0,2 %	FW
10/08	Tendance irrégulière à la Bourse de Stockholm, l'indice OMXS30 recule de 0,1 %	FW

Communiqués

20/08	Invitation to Saniona Q2 investor call on 27 August 2026	AQ
18/08	Saniona on the equity and milestone upside in the AstronauTx deal	AQ
10/08	AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration	AQ
23/06	Saniona: Our take on the SAN2668 R&D day	AQ
11/06	Three shots on goal: Saniona prepares to enter the clinic	AQ
04/06	Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies	AQ
28/05	Saniona (Q1 Review): Setting up for the long run	AQ
27/05	Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026	AQ
26/05	SANA : Interim Report Q1 2026	PU
26/05	Saniona publishes its interim report for the first quarter of 2026	AQ
20/05	Invitation to Saniona Q1 investor call on 26 May 2026	AQ
30/04	Saniona publishes its Annual Report for 2025	AQ
27/04	SANA : The board's statement pursuant to Chapter 19, Section 22 of the Swedish companies Act	PU
24/04	SANA : Notice of annual shareholders' meeting 2026	PU
24/04	SANA : Proposal for resolution on LTI 2026	PU
24/04	SANA : Notice of Saniona AB annual shareholders' meeting	PU
24/04	Notice of Saniona AB annual shareholders’ meeting	AQ
12/03	Saniona enters clinical execution phase following transformational year	AQ
12/03	Meet Saniona at several conferences during the spring	AQ
03/03	Saniona (Q4 review): Moving forward nicely	AQ
26/02	Saniona publishes its year-end report for 2025	AQ
20/02	Invitation to Saniona Q4 & year-end investor call on 26 February 2026	AQ
17/12	Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs	AQ
01/12	Saniona comments on major advancements during third quarter	AQ
28/11	Saniona (Q3 Review) - Gearing up for clinical development	AQ